Assessment of proliferation of squamous, Barrett's, and gastric mucosa in patients with columnar lined Barrett's oesophagus

EDITOR,—I comment on the interesting paper by Iftekhar et al on assessment of proliferation in oesophageal squamous, Barrett's, and gastric epithelium by flow cytometric evaluation of Ki67 immunolabelling (Gut 1992; 33: 733-7). The authors found that biopsy specimens from squamous lined oesophagus contained cell populations with a higher percentage of Ki67 positive cells than Barrett's, and gastric mucosal biopsy specimens. Barrett's and gastric mucosal biopsy specimens had similar percentages of Ki67 positive cells.

Their results may be misleading as the proportion of stromal cells in Barrett's mucosa greatly exceeds that in gastric and squamous mucosal biopsy specimens, which have over 90% pure epithelial populations; stromal cells are not excluded from the total cell count by their technique and dilute the epithelial cell population. Thus the finding that Barrett's mucosal biopsy specimens contain a similar percentage of Ki67 cells to gastric biopsy specimens (by this technique) is more likely to imply a considerably higher epithelial Ki67 labelling index in Barrett's than in gastric epithelial cell (as opposed to the total mucosal cell population).

This agrees with the studies performed on stained sections of mucosal biopsy specimens, including our own.1 In our study of epithelial proliferation in Barrett's oesophagus we used PCNA immunostaining of specialised Barrett's, junctional, and metaplasia to evaluate proliferation in the epithelial cells only (excluding stromal cells). In our study specialised type Barrett's had a higher proportion of cells in cycle and an expansion of the proliferative compartment out of the crypt and into the lumenal and gland cell compartments; implying a higher level of proliferative activity in the specialised Barrett's than in the other types of metaplasia. Our findings are consistent with the proved association of specialised type Barrett's epithelium with malignant change (in smokers).2 4

MICHAEL GRAY
Marine Villa, Little Lane, Parkgate, Wirral L4 5SD

References


OVERVIEW OF SCREENING AND MANAGEMENT OF FAMILIAL ADENOMATOUS POLYPOSIS

EDITOR,—In their review article Rhodes and Hawkins (Gut 1992; 33: 576-9) discuss strategies for hepatitis B vaccination.

Immunisation. With regard to the need for booster vaccinations it seems to us that option I (no booster and reliance on immunological memory) has gained additional strength by new in vivo and in vitro data. Some of these have already been mentioned in the addendum. Our own data1 have been supported by the findings of Jilg's group.2 To our knowledge, not a single case of clinically evident hepatitis B or carriage following hepatitis B virus infection has been reported in a confirmed serologically to hepatitis B vaccine. A spot ELISA assay, which visualise the specific immunoglobulin production of either IgG or IgM class by individuals. Many stimulated B cells in vitro, is able to show latent immunological memory and adds further support to this strategy.3 Long term follow up data confirm the presence of persisting circulating B cell memory despite undetectable anti-HBs in the serum seven to nine years after the first vaccination.4 Further studies with an even longer interval are in progress. Moreover, follow up data carefully monitoring the course of events after accidental infection (such as needlestick injuries) will give additional information.

Omitting booster vaccinations completely despite theoretical objections, in all those who have been known to react to the initial vaccination series with an anti-HBs titre in excess of 100 IU/l, seems to be a perfectly reasonable alternative to expensive, complicated, and probably unnecessary booster immunisation programmes. This policy is actually being evaluated on a worldwide scale at present (be it uncontrolled) because many vaccines with known responder status will not have received a booster vaccination.

W JMISWANS
Harbour Hospital, Hargrave 2, 3011 TD Rotterdam The Netherlands


REFERENCES

Strategies for hepatitis B infection.

P J Wismans and J van Hattum

Gut 1993 34: 575
doi: 10.1136/gut.34.4.575-c

Updated information and services can be found at:
http://gut.bmj.com/content/34/4/575.4.citation

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/